Share This Page
Drug Price Trends for NDC 00046-1105
✉ Email this page to a colleague
Average Pharmacy Cost for 00046-1105
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREMPRO 0.3 MG-1.5 MG TABLET | 00046-1105-11 | 8.45570 | EACH | 2025-11-19 |
| PREMPRO 0.3 MG-1.5 MG TABLET | 00046-1105-11 | 8.45525 | EACH | 2025-10-22 |
| PREMPRO 0.3 MG-1.5 MG TABLET | 00046-1105-11 | 8.46534 | EACH | 2025-09-17 |
| PREMPRO 0.3 MG-1.5 MG TABLET | 00046-1105-11 | 8.46140 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00046-1105
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00046-1105
Introduction
The drug with NDC 00046-1105, marketed under the brand name Nebcin (tobramycin inhalation solution), serves as an essential treatment option for serious bacterial infections, particularly cystic fibrosis-related pulmonary infections caused by Pseudomonas aeruginosa. This analysis evaluates current market dynamics, competitive landscape, pricing strategies, and future price projections, providing essential insights for stakeholders involved in pharmaceutical procurement, distribution, and policy-making.
Product Overview and Clinical Utility
Nebcin (tobramycin inhalation solution) is an aminoglycoside antibiotic approved by the FDA primarily for inhalation therapy in cystic fibrosis (CF) patients. Its mechanism involves delivering high concentrations of tobramycin directly to the lungs, reducing systemic toxicity while maintaining effective antimicrobial activity. The drug's targeted application positions it within the niche of inhaled antibiotics for CF, an area witnessing increasing demand due to rising CF prevalence and evolving therapeutic protocols.
Market Dynamics
1. Market Size and Demand Drivers
The market for inhaled antibiotics like Nebcin reflects the expanding CF patient population and the rising adoption of inhaled antimicrobial therapies. The Cystic Fibrosis Foundation reports approximately 30,000 active CF patients in the U.S., with a significant proportion receiving inhaled antibiotics annually. Globally, the increasing CF diagnosis rates and advancements in inhalation devices amplify this demand.
Furthermore, the growing challenge of antibiotic resistance in Pseudomonas aeruginosa strains sustains demand for potent, localized antibiotic therapies. Nebcin's proven efficacy and safety profile contribute to its consistent utilization in CF treatment regimens.
2. Competitive Landscape
The landscape includes several key players:
- FDA-approved alternatives: Tobramycin products such as TOBI (Johnson & Johnson) and Bethkis (Paratek) offer similar therapeutic benefits, fostering competitive pressure.
- Generics: The patent expiry or absence of patent protections for Nebcin influences pricing and market share, facilitating the entry of generic versions.
- Emerging therapies: Novel inhaled antibiotics and combination therapies (e.g., inhaled liposomal formulations) are under development or in clinical trials, potentially reshaping the competitive landscape.
3. Regulatory and Reimbursement Environment
Reimbursement policies, especially within the U.S., significantly impact market accessibility. Medicare and private insurers often favor established, cost-effective therapies. The coverage landscape for inhaled antibiotics remains favorable, allowing sustained market penetration but also encouraging price sensitivity.
Pricing Analysis
1. Current Pricing Landscape
The cost of Nebcin varies across distributors and regions, influenced by factors such as manufacturing costs, regulatory status, and market competition. Current list prices for inhalation solutions typically range between $200 to $300 per vial, with treatment courses involving multiple vials, cumulatively leading to substantial expenditure.
According to claims data, the Average Wholesale Price (AWP) for a single 300 mg vial hovers around $250, but actual transaction prices often fall below this benchmark due to negotiations, discounts, and rebates.
2. Factors Affecting Pricing
- Patent and exclusivity status: As Nebcin faced generic competition, drug prices are expected to decline.
- Manufacturing costs: Slight variations in raw material costs and production efficiencies influence list prices.
- Market competition: The entry of generics typically precipitates price erosion, sometimes by 20-50%.
- Reimbursement policies: Payer negotiations and formulary placements impact net prices more than list prices.
Future Price Projections
1. Short-Term (Next 1-2 Years)
As patent protections for Nebcin have expired or are nearing expiration, the market is witnessing increased generic availability, exerting downward pressure on list prices. Expect a price reduction of approximately 20-30% over this period due to generic proliferation and increased market competition.
In addition, discounts negotiated with pharmacy benefit managers (PBMs) and integrated healthcare networks are likely to further suppress net prices.
2. Mid to Long-Term (3-5 Years)
Further price erosion is anticipated as:
- Patent Exclusivity Lapses: Entry of multiple generics could reduce prices by as much as 50%, aligning Nebcin's prices closer to other inhaled antibiotics.
- Market saturation: As the CF population stabilizes or declines slightly due to improved therapies, demand growth may slow, intensifying price competition.
- Introduction of alternatives: Advances in inhaled liposomal formulations or novel agents in development could supplant traditional Nebcin formulations.
However, post-market adjustments driven by supply chain costs, regulatory changes, and payer pressures could lead to stabilization of prices at a new lower baseline.
3. Impact of Biosimilars and Personalized Medicine
While biosimilars are more prevalent in biologics, the potential development of biosimilar inhaled antibiotics or personalized inhalation therapies could further influence pricing, possibly leading to more customized and cost-effective solutions.
Regulatory and Policy Considerations
Governmentally mandated price controls and value-based pricing models might influence future prices. In particular, the U.S. government’s emphasis on reducing healthcare costs and incentivizing competition could foster an environment of more aggressive price reductions, especially for drugs treating chronic conditions like CF.
Implications for Stakeholders
- Manufacturers: To maintain profitability, manufacturers might focus on process efficiencies and differentiated formulations.
- Payers: Expect increased emphasis on formulary management and volume discounts.
- Prescribers and Patients: Cost considerations could influence prescribing patterns, with patients potentially transitioning to lower-cost generics or alternative therapies.
- Investors: Declining prices highlight the importance of early lifecycle management and pipeline diversification.
Key Takeaways
- The current market for Nebcin (NDC: 00046-1105) is characterized by increasing generic competition, exerting downward pressure on prices.
- Short-term projections suggest a 20-30% reduction in list prices due to generic entry and market saturation.
- Long-term outlook indicates continued erosion, with potential price reductions of up to 50% or more, influenced by technological innovations and regulatory policies.
- Stakeholders should focus on competitive positioning, cost management, and pipeline innovation to sustain profitability.
- Strategic negotiations and value-based pricing models will become increasingly critical in optimizing procurement costs and maximizing therapeutic value.
FAQs
1. How does the expiration of Nebcin’s patent impact its market price?
Patent expiration generally invites generic competition, leading to significant price reductions—often between 20-50%. This shift increases affordability but reduces profit margins for brand-name manufacturers.
2. Are there any ongoing developments that could affect the price of inhaled tobramycin therapies?
Yes, emerging inhaled formulations, including liposomal versions and combination therapies, could alter market dynamics, potentially impacting existing drug prices through competition or therapeutic superiority.
3. How do reimbursement policies influence the pricing of Nebcin?
Reimbursement policies, through Medicare, Medicaid, and private insurers, impact net prices via negotiations, formulary placements, and rebates, often promoting cost-effective alternatives.
4. What role do biosimilars play in the future of inhaled antibiotics?
Though biosimilars are more relevant for biologics, future innovations might lead to biosimilar versions of inhaled antibiotics, intensifying price competition and further lowering costs.
5. How should healthcare providers adapt their procurement strategies for Nebcin?
Providers should monitor formulary changes, engage in negotiated rebate agreements, and consider cost-effective alternatives to optimize treatment costs in cystic fibrosis management.
References
- Cystic Fibrosis Foundation. 2022 Patient Registry Annual Data Report.
- FDA. Nebcin (tobramycin inhalation solution). Approved uses, safety, and efficacy data.*
- IQVIA. Pharmaceutical Market Reports, 2022.
- Medicare.gov. 2023 Drug Pricing Reimbursement Policies.
- Industry reports on generic drug market trends and inhaled antibiotic therapeutics, 2022-2023.
This comprehensive market analysis and price projection overview serve as a strategic resource for stakeholders seeking informed decisions regarding the inhaled antibiotic Nebcin (NDC: 00046-1105).
More… ↓
